Here are relevant reports on : lung-cancer-treatment-market
-
Lung Cancer Surgery Market by Instrument ((Clamps, Foreceps, Trocars, Retractors, Scissors), Monitoring & Endoscopic Devices), Procedure (Thoracotomy (Lobectomy, Pneumonectomy, Segmentectomy, Sleeve Resection), MIS), Volume Data & Region - Global Forecast to 2026
The global lung cancer surgery market growth is primed to transition from $5.4 billion in 2020 to $6.7 billion by 2026, showcasing a strong CAGR of 3.8%. Market growth is largely driven by factors such as the technological advancements in lung cancer treatment, the increasing incidence and prevalence of lung cancer, the growing trend of smoking tobacco, the rising geriatric population, the increasing emphasis on early diagnosis and treatment of cancers, and the availability of reimbursement.
- Published: June 2021
- Price: $ 4950
- TOC Available:
-
Digital Biomarkers Market by Type (Physiological, Vocal, Idiosyncratic), Therapy [Cardio, Onco (Lung, Breast Cancer), Mental Health, Neuro], Application [Clinical Research (Phase IV)], End User (Pharma & Biotech Companies, CROs) – Global Forecast to 2031
The global digital biomarkers market is projected to reach USD 17.73 billion by 2031, growing at a CAGR of 19.1% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Oncology Nutrition Market by Cancer Type (Head & Neck, Stomach & Gastrointestinal, Liver, Pancreatic, Esophageal, Lung, Breast, Blood) - Global Forecast to 2023
The global oncology nutrition market is expected to reach USD 2.21 Billion by 2023 from USD 1.46 Billion in 2018, at a CAGR of 8.7%. Factors such as shifting focus from parenteral to enteral nutrition, increasing incidence of cancer, growing demand for nutritional feeding in the homecare sector, rising number of patients being treated for malnutrition, and increasing quality of clinical research on nutritional interventions are driving the market growth. The prominent players in the oncology nutrition market are Abbott Laboratories (US), Nestle S.A. (Switzerland), Danone (France), Fresenius Kabi AG (Germany), and B. Braun Melsungen AG (Germany).
- Published: April 2018
- Price: $ 16000
- TOC Available:
-
Tumor Ablation Market by Technology (Radiofrequency, Microwave, Cryoablation, HIFU), Product (Systems, Consumables), Application (Liver, Lung, Kidney, Bone Cancer), Procedure (Surgical, Laparoscopic, Percutaneous), and End User - Global Forecast to 2031
The global tumor ablation market is projected to reach USD 1.89 billion by 2031, growing at a CAGR of 11.4% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Companion Diagnostics Market by Product (Assays, Kits, & Reagents, Instruments, Software), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious), Drug Class (MAB, Cell & Gene Therapy) - Global Forecast to 2031
The global companion diagnostics market is projected to reach USD 11.57 billion by 2031, growing at a CAGR of 12.9% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: June 2026
- Price: $ 4950
- TOC Available:
-
Respiratory Diagnostics Market by Product & Services (Instrument & Devices), Test type (Mechanical, OSA, Imaging, Molecular Test), Disease (Tuberculosis, COPD, Lung Cancer ) and Diagnosis Type (Syndromic, Aetiological, Prognosis) - Global Forecast to 2030
Global respiratory diagnostics market valued at $5.84B in 2024, reached $6.17B in 2025, and is projected to grow at a robust 6.5% CAGR, hitting $9.02B by 2030. The major factors driving the growth of this market include the rising incidence of respiratory disorders, the expanding geriatric population and the rise in sedentary lifestyles, growing awareness about respiratory health, and advancements in diagnostic technologies.
- Published: February 2025
- Price: $ 4950
- TOC Available:
-
European NGS Services Market by Technology (SBS, SBL, SMRT, Pyrosequencing), Application (Exome Sequencing, CHIP-Seq), End User (Pharmaceutical Companies, Hospital), Disease [Oncology (Prostate, Lung, & Breast Cancer), Rare Diseases) - Forecast to 2020
The NGS services market in Europe is expected to reach USD 1,152 Million by 2020 from USD 444 Million in 2015, at a CAGR of 21% from 2015 to 2020. Factors such as rising preference of NGS over other platforms; rapid and cost-efficient sequencing; rising prevalence of inherited diseases; application of genomics in drug discovery; growing prevalence of cancer and other malignant diseases; and partnerships among companies, R&D centers, and universities are expected to drive market growth. However, high dependence on grants for R&D, lack of analytics, and stringent reimbursement policies are likely to restrict the growth of this market to a certain extent.
- Published: October 2015
- Price: $ 4950
- TOC Available:
-
Neuroblastoma Cancer Market by Diagnostics (MIBG Scan, Imaging, Urine Analysis, Biopsy), Treatment (Surgery, Chemotherapy, Radiation therapy, Stem Cell Transplant, Immunotherapy), Staging, Pipeline, Regulatory, Reimbursement - Global Forecast to 2021
Neuroblastoma is a rare extracranial solid tumor cancer that develops from immature nerve cells found in several areas of the body. It is the most common extracranial solid tumor in childhood.
- Published: December 2026
- Price: $ 4950
- TOC Available:
-
PEGylated Proteins Market by Consumables (PEGylation Kits, Reagents), Services, Protein Type (mAbs, Interferons), Application (Cancer Treatment, Chronic Kidney Diseases), End-User (Pharmaceutical & Biotechnology Companies)- Global Forecast to 2021
The global PEGylated proteins market size is projected to grow at a CAGR of 10.5%. The major drivers for the market include increase in R&D spending of pharmaceutical & biotechnology companies, growth in biologics sector, high prevalence of lifestyle disease, increasing focus on strategies to improve protein stability and circulating half-life. The rising opportunities in emerging markets and top-selling biologics drugs going off-patent in the near future will provide new growth opportunities for this market.
- Published: November 2016
- Price: $ 4950
- TOC Available:
-
Particle Therapy Market by Type (Proton Therapy, Heavy Ion), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate), Application (Treatment, Research) - Global Forecast to 2028
The global particle therapy market, valued at US$0.6 billion in 2022, stood at US$0.7 billion in 2023 and is projected to advance at a resilient CAGR of 8.2% from 2023 to 2028, culminating in a forecasted valuation of US$1.1 billion by the end of the period. Many factors, such as technological advancements, funding and reimbursement, strong healthcare funding, active research funding, a clear regulatory framework, growing minimally invasive procedure adoption, and the presence of key market players in developing regions are driving the growth of the particle therapy market
- Published: November 2023
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
